Polyvascular Disease: A Narrative Review of Risk Factors, Clinical Outcomes and Treatment
Tannu M, Hess C, Gutierrez J, Lopes R, Swaminathan R, Altin S, Rao S. Polyvascular Disease: A Narrative Review of Risk Factors, Clinical Outcomes and Treatment. Current Cardiology Reports 2024, 26: 505-520. PMID: 38743352, DOI: 10.1007/s11886-024-02063-0.Peer-Reviewed Original ResearchGlobal burdenIncreased riskPolyvascular diseaseIncreased risk of bleedingIncreased risk of adverse outcomesRisk factorsVascular territoriesLow-dose anticoagulationLevels of atherogenic lipoproteinsRisk of adverse outcomesAssociated with increased riskLipid-lowering therapyRisk of bleedingAdverse cardiac eventsType 2 diabetes mellitusHigh-risk subgroupsDose of therapyReview of risk factorsReduce disease progressionPresence of atherosclerosisOptimal timingP2Y12 inhibitorsTreatment intensificationEscalating treatmentIschemic benefitDuration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis
Park D, Hu J, Campbell G, Goldwag K, Kelsey M, Altin S, Gallegos-Kattán C, Nanna M. Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-analysis. Journal Of The Society For Cardiovascular Angiography & Interventions 2024, 3: 101859. PMID: 39131993, PMCID: PMC11307649, DOI: 10.1016/j.jscai.2024.101859.Peer-Reviewed Original ResearchMonths of DAPTDuration of dual antiplatelet therapyNet adverse clinical eventsType 2 diabetes mellitusDual antiplatelet therapyAcute coronary syndromeRandomized controlled trialsSensitivity analysis of trialsPercutaneous coronary interventionCoronary interventionNo significant differenceAntiplatelet therapyAnalysis of trialsCoronary syndromeControlled trialsMeta-analysis of patientsStent thrombosisMeta-analysisDAPT durationClinicians greater flexibilityStudy-level meta-analysisOptimal duration of dual antiplatelet therapyHigher risk of adverse eventsPostpercutaneous coronary interventionRisk of adverse events
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply